Tempest Therapeutics, Inc. (TPST) 10-Year Financial Performance & Capital Metrics

TPST • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

AboutTempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.Show more

Revenue $0
EBITDA -$42M -44.7%
Net Income -$42M -41.9%
EPS (Diluted) -1.50 +21.5%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -182.35% -38.7%
ROIC -507.48% -99.5%
Debt/Equity 0.80 +4.1%
Interest Coverage -31.93 -58.7%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Weak momentum: RS Rating 2 (bottom 2%)
✗Shares diluted 81.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-1.51%

EPS CAGR

10Y-

5Y-

3Y-

TTM-323.38%

ROCE

10Y Avg-68.72%

5Y Avg-77.88%

3Y Avg-89.43%

Latest-121.01%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.43	53.07	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	12.18B	45.44	25.82	18.49%	29.63%	31.37%	5.2%	0.09
BBOTBridgeBio Oncology Therapeutics Inc.	919.87M	11.50	25			-25.73%
INBXInhibrx Biosciences, Inc.	1.04B	71.80	0.62	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.1B	6.14	-2.91		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.32B	7.63	-3.23	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.12B	11.52	-6.30			-33.24%		0.01
ZLABZai Lab Limited	2.09B	18.82	-7.24	49.59%	-46.83%	-27.21%		0.18

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	277K	653K	295K	0	0	0	0	0	0	0
Revenue Growth %	-0.97%	1.36%	-0.55%	-1%	-	-	-	-	-	-
Cost of Goods Sold+	2.25M	5.4M	28K	32K	0	815K	0	0	0	389K
COGS % of Revenue	8.12%	8.27%	0.09%	-	-	-	-	-	-	-
Gross Profit+	-1.97M	-4.75M	267K	-32K	-1.05M	-815K	0	0	0	-389K
Gross Margin %	-7.12%	-7.27%	0.91%	-	-	-	-	-	-	-
Gross Profit Growth %	-1.2%	-1.41%	1.06%	-1.12%	-31.88%	0.23%	1%	-	-	-
Operating Expenses+	70.03M	70.86M	20.45M	23.08M	44.35M	18.48M	26.99M	34.64M	29.16M	41.64M
OpEx % of Revenue	252.81%	108.52%	69.34%	-	-	-	-	-	-	-
Selling, General & Admin	51.59M	49.22M	5.93M	8.66M	16.5M	4.09M	9.82M	12.11M	11.66M	13.55M
SG&A % of Revenue	186.26%	75.38%	20.09%	-	-	-	-	-	-	-
Research & Development	18.43M	21.64M	14.53M	14.43M	27.84M	14.39M	17.17M	22.53M	17.5M	28.48M
R&D % of Revenue	66.55%	33.14%	49.24%	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0	0	0	0	-389K
Operating Income+	-72M	-81.01M	-20.48M	-23.12M	-45.4M	-19.3M	-26.99M	-34.64M	-29.16M	-42.03M
Operating Margin %	-259.92%	-124.06%	-69.43%	-	-	-	-	-	-	-
Operating Income Growth %	-0.5%	-0.13%	0.75%	-0.13%	-0.96%	0.57%	-0.4%	-0.28%	0.16%	-0.44%
EBITDA+	-70.71M	-78.77M	-20.45M	-23.08M	-44.35M	-18.48M	-26.61M	-34M	-28.78M	-41.64M
EBITDA Margin %	-255.28%	-120.63%	-69.34%	-	-	-	-	-	-	-
EBITDA Growth %	-0.49%	-0.11%	0.74%	-0.13%	-0.92%	0.58%	-0.44%	-0.28%	0.15%	-0.45%
D&A (Non-Cash Add-back)	1.29M	2.24M	28K	32K	1.05M	815K	374K	638K	381K	389K
EBIT	-73.14M	-82.06M	-84.3M	-27.04M	-44.57M	-19.21M	-27.02M	-34.09M	-28.04M	-40.53M
Net Interest Income+	0	0	0	0	264K	90K	-1.28M	-1.07M	-334K	183K
Interest Income	0	0	0	0	264K	90K	1.28K	549K	1.11M	1.5M
Interest Expense	436K	659K	0	134K	0	0	1.28M	1.62M	1.45M	1.32M
Other Income/Expense	-1.15M	-6.45M	-64.1M	-4.06M	831K	90K	-1.32M	-1.07M	-334K	183K
Pretax Income+	-73.14M	-82.06M	-84.59M	-27.18M	-44.57M	-19.21M	-28.3M	-35.71M	-29.49M	-41.84M
Pretax Margin %	-264.06%	-125.66%	-286.73%	-	-	-	-	-	-	-
Income Tax+	75K	201K	67K	-169K	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-73.22M	-82.26M	-84.58M	-27.19M	-44.57M	-19.12M	-28.3M	-35.71M	-29.49M	-41.84M
Net Margin %	-264.33%	-125.97%	-286.71%	-	-	-	-	-	-	-
Net Income Growth %	-0.48%	-0.12%	-0.03%	0.68%	-0.64%	0.57%	-0.48%	-0.26%	0.17%	-0.42%
Net Income (Continuing)	-73.22M	-82.26M	-84.59M	-27.18M	-44.57M	-19.21M	-28.3M	-35.71M	-29.49M	-41.84M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	12.76M	2.17M	1.32M	0	0	0	0	0
EPS (Diluted)+	-608.25	-575.73	-72406.33	-263.65	-48.77	-612.56	-7.80	-3.18	-1.91	-1.50
EPS Growth %	-0.24%	0.05%	-124.76%	1%	0.82%	-11.56%	0.99%	0.59%	0.4%	0.21%
EPS (Basic)	-608.25	-575.73	-72406.33	-263.65	-48.77	-612.56	-7.80	-3.18	-1.91	-1.50
Diluted Shares Outstanding	120.38K	142.88K	1.17K	103.14K	913.78K	31.21K	291.56K	888.38K	15.42M	27.9M
Basic Shares Outstanding	120.38K	142.88K	1.17K	103.14K	913.78K	31.21K	291K	888K	15.42M	27.9M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	129.86M	116.44M	19.74M	83.42M	71.13M	19.82M	68.96M	32.95M	40.36M	31.47M
Cash & Short-Term Investments	126.86M	114.39M	67.2M	77.72M	63.51M	18.82M	51.83M	31.23M	39.23M	30.27M
Cash Only	43.42M	43.93M	15.7M	73.33M	63.51M	18.82M	51.83M	31.23M	39.23M	30.27M
Short-Term Investments	83.44M	70.46M	51.5M	4.38M	0	0	0	0	0	0
Accounts Receivable	0	0	1.03M	2.33M	1.28M	260K	15M	450K	0	0
Days Sales Outstanding	-	-	1.28K	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	3M	2.06M	1.58M	3.37M	6.34M	59K	553K	263K	96K	535K
Total Non-Current Assets+	8.75M	6.1M	74K	652K	3.84M	3.04M	4.28M	13.14M	11.24M	10.01M
Property, Plant & Equipment	8.31M	5.57M	3.11M	0	3.33M	2.99M	4.16M	12.71M	10.79M	9.53M
Fixed Asset Turnover	0.03x	0.12x	0.09x	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	439K	504K	146K	439K	0	0	0	0	0	388K
Other Non-Current Assets	0	23K	-3.19M	213K	507K	51K	111K	429K	448K	97K
Total Assets+	138.61M	122.54M	19.81M	84.07M	74.97M	22.86M	73.24M	46.09M	51.6M	41.49M
Asset Turnover	0.00x	0.01x	0.01x	-	-	-	-	-	-	-
Asset Growth %	1.11%	-0.12%	-0.84%	3.24%	-0.11%	-0.7%	2.2%	-0.37%	0.12%	-0.2%
Total Current Liabilities+	11.24M	13.21M	4.09M	9.82M	12.52M	3.22M	20.03M	7.28M	9.41M	14.22M
Accounts Payable	3.35M	2.18M	2.24M	2M	1.5M	1.07M	991K	1.11M	845K	2.45M
Days Payables Outstanding	544.01	147.53	29.23K	22.79K	-	479.65	-	-	-	2.3K
Short-Term Debt	0	0	174K	189K	1.96M	0	0	0	4.29M	6.35M
Deferred Revenue (Current)	0	0	334K	0	0	0	0	0	0	0
Other Current Liabilities	7.89M	11.03M	2.29M	7.63M	7.02M	774K	912K	1.25M	1.79M	0
Current Ratio	11.55x	8.82x	4.82x	8.50x	5.68x	6.15x	3.44x	4.53x	4.29x	2.21x
Quick Ratio	11.55x	8.82x	4.82x	8.50x	5.68x	6.15x	3.44x	4.53x	4.29x	2.21x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	520K	1.12M	738K	1.14M	2.58M	88.43M	17.09M	20.7M	15.42M	8.14M
Long-Term Debt	0	0	599K	383K	168K	0	15.07M	10.37M	6.26M	0
Capital Lease Obligations	0	0	0	0	2.4M	1.73M	2.03M	10.33M	9.16M	8.14M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	520K	1.12M	139K	752K	16K	86.71M	0	0	0	0
Total Liabilities	11.76M	14.32M	4.83M	10.95M	15.1M	91.66M	37.12M	27.98M	24.84M	22.36M
Total Debt+	0	0	773K	572K	4.52M	2.44M	18.54M	22.11M	20.66M	15.37M
Net Debt	-43.42M	-43.93M	-16.85M	-72.76M	-58.99M	-16.38M	-33.29M	-9.12M	-18.57M	-14.9M
Debt / Equity	-	-	0.05x	0.01x	0.08x	-	0.51x	1.22x	0.77x	0.80x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-165.14x	-122.93x	-	-172.51x	-	-	-21.05x	-21.41x	-20.12x	-31.93x
Total Equity+	126.85M	108.22M	14.98M	73.12M	59.87M	-68.79M	36.12M	18.11M	26.77M	19.13M
Equity Growth %	1.29%	-0.15%	-0.86%	3.88%	-0.18%	-2.15%	1.53%	-0.5%	0.48%	-0.29%
Book Value per Share	1053.77	757.41	12827.91	708.99	65.52	-2204.20	123.87	20.39	1.74	0.69
Total Shareholders' Equity	126.85M	108.22M	2.23M	70.95M	58.55M	-68.79M	36.12M	18.11M	26.77M	19.13M
Common Stock	27K	36K	36K	13K	18K	1K	7K	11K	22K	44K
Retained Earnings	-167.92M	-250.18M	-136.89M	-164.09M	-208.65M	-71.76M	-100.06M	-135.77M	-165.26M	-207.11M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-170K	-60K	-19K	148K	165K	0	0	0	0	0
Minority Interest	0	0	12.76M	2.17M	1.32M	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-50.29M	-61.73M	-20.34M	-23.65M	-41.22M	-19.02M	-25.96M	-31.07M	-27.36M	-33.03M
Operating CF Margin %	-181.54%	-94.54%	-68.95%	-	-	-	-	-	-	-
Operating CF Growth %	-0.64%	-0.23%	0.67%	-0.16%	-0.74%	0.54%	-0.36%	-0.2%	0.12%	-0.21%
Net Income	-73.22M	-82.26M	-84.58M	-27.19M	-44.57M	-19.21M	-28.3M	-35.71M	-29.49M	-41.84M
Depreciation & Amortization	1.29M	2.24M	1.65M	32K	1.05M	339K	374K	638K	381K	389K
Stock-Based Compensation	19.34M	9.21M	6.89M	1.43M	0	453K	1.1M	1.56M	2.55M	5.3M
Deferred Taxes	0	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	0	0	66.05M	0	4.35M	470K	1.48M	1.57M	1.88M	1.51M
Working Capital Changes	-532K	4.58M	-1.84M	1.04M	-2.05M	-1.07M	-613K	868K	-2.68M	1.61M
Change in Receivables	0	0	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	-171K	-1.18M	-1.45M	320K	-469K	-574K	-209K	1K	-263K	1.6M
Cash from Investing+	-38.29M	8.29M	458K	1.12M	3.99M	-6K	-97K	-562K	-170K	-435K
Capital Expenditures	-5.23M	-2.59M	-158K	-36K	-397K	-50K	-135K	-562K	-170K	-435K
CapEx % of Revenue	18.88%	3.96%	0.54%	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-681K	0	-1.45M	0	0	44K	38K	0	0	0
Cash from Financing+	125.39M	54.15M	-4.46M	78.55M	26.94M	34.6M	59.06M	11.4M	35.6M	24.5M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	0	0	33.32M	0	-401K	10.64M	0	0	307K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-55.52M	-64.32M	-20.34M	-23.68M	-41.62M	-19.07M	-26.09M	-31.63M	-27.53M	-33.46M
FCF Margin %	-200.42%	-98.5%	-68.96%	-	-	-	-	-	-	-
FCF Growth %	-0.66%	-0.16%	0.68%	-0.16%	-0.76%	0.54%	-0.37%	-0.21%	0.13%	-0.22%
FCF per Share	-461.18	-450.17	-17417.81	-229.63	-45.55	-610.93	-89.49	-35.61	-1.79	-1.20
FCF Conversion (FCF/Net Income)	0.69x	0.75x	0.24x	0.87x	0.92x	0.99x	0.92x	0.87x	0.93x	0.79x
Interest Paid	0	0	0	0	0	0	0	1.54M	1.25M	1.18M
Taxes Paid	0	0	0	0	0	0	0	18K	191K	54K

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-80.38%	-69.99%	-137.3%	-61.73%	-67.02%	-	-78.36%	-131.7%	-131.42%	-182.35%
Return on Invested Capital (ROIC)	-81.61%	-82.26%	-47.75%	-8335.1%	-5474.16%	-	-	-439.59%	-254.36%	-507.48%
Gross Margin	-711.91%	-727.11%	90.51%	-	-	-	-	-	-	-
Net Margin	-26432.85%	-12597.24%	-28670.51%	-	-	-	-	-	-	-
Debt / Equity	-	-	0.05x	0.01x	0.08x	-	0.51x	1.22x	0.77x	0.80x
Interest Coverage	-165.14x	-122.93x	-	-172.51x	-	-	-21.05x	-21.41x	-20.12x	-31.93x
FCF Conversion	0.69x	0.75x	0.24x	0.87x	0.92x	0.99x	0.92x	0.87x	0.93x	0.79x
Revenue Growth	-97.15%	135.74%	-54.82%	-100%	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Tempest Therapeutics, Inc. (TPST) grew revenue by 0.0% over the past year. Growth has been modest.

Tempest Therapeutics, Inc. (TPST) reported a net loss of $36.1M for fiscal year 2024.

Dividend & Returns

Tempest Therapeutics, Inc. (TPST) has a return on equity (ROE) of -182.3%. Negative ROE indicates the company is unprofitable.

Tempest Therapeutics, Inc. (TPST) had negative free cash flow of $33.4M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Tempest Therapeutics, Inc. (TPST) 10-Year Financial Performance & Capital Metrics

TPST • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

Revenue $0
EBITDA -$42M -44.7%
Net Income -$42M -41.9%
EPS (Diluted) -1.50 +21.5%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -182.35% -38.7%
ROIC -507.48% -99.5%
Debt/Equity 0.80 +4.1%
Interest Coverage -31.93 -58.7%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Weak momentum: RS Rating 2 (bottom 2%)
✗Shares diluted 81.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-1.51%

EPS CAGR

10Y-

5Y-

3Y-

TTM-323.38%

ROCE

10Y Avg-68.72%

5Y Avg-77.88%

3Y Avg-89.43%

Latest-121.01%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.43	53.07	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	12.18B	45.44	25.82	18.49%	29.63%	31.37%	5.2%	0.09
BBOTBridgeBio Oncology Therapeutics Inc.	919.87M	11.50	25			-25.73%
INBXInhibrx Biosciences, Inc.	1.04B	71.80	0.62	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.1B	6.14	-2.91		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.32B	7.63	-3.23	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.12B	11.52	-6.30			-33.24%		0.01
ZLABZai Lab Limited	2.09B	18.82	-7.24	49.59%	-46.83%	-27.21%		0.18

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	277K	653K	295K	0	0	0	0	0	0	0
Revenue Growth %	-0.97%	1.36%	-0.55%	-1%	-	-	-	-	-	-
Cost of Goods Sold+	2.25M	5.4M	28K	32K	0	815K	0	0	0	389K
COGS % of Revenue	8.12%	8.27%	0.09%	-	-	-	-	-	-	-
Gross Profit+	-1.97M	-4.75M	267K	-32K	-1.05M	-815K	0	0	0	-389K
Gross Margin %	-7.12%	-7.27%	0.91%	-	-	-	-	-	-	-
Gross Profit Growth %	-1.2%	-1.41%	1.06%	-1.12%	-31.88%	0.23%	1%	-	-	-
Operating Expenses+	70.03M	70.86M	20.45M	23.08M	44.35M	18.48M	26.99M	34.64M	29.16M	41.64M
OpEx % of Revenue	252.81%	108.52%	69.34%	-	-	-	-	-	-	-
Selling, General & Admin	51.59M	49.22M	5.93M	8.66M	16.5M	4.09M	9.82M	12.11M	11.66M	13.55M
SG&A % of Revenue	186.26%	75.38%	20.09%	-	-	-	-	-	-	-
Research & Development	18.43M	21.64M	14.53M	14.43M	27.84M	14.39M	17.17M	22.53M	17.5M	28.48M
R&D % of Revenue	66.55%	33.14%	49.24%	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0	0	0	0	-389K
Operating Income+	-72M	-81.01M	-20.48M	-23.12M	-45.4M	-19.3M	-26.99M	-34.64M	-29.16M	-42.03M
Operating Margin %	-259.92%	-124.06%	-69.43%	-	-	-	-	-	-	-
Operating Income Growth %	-0.5%	-0.13%	0.75%	-0.13%	-0.96%	0.57%	-0.4%	-0.28%	0.16%	-0.44%
EBITDA+	-70.71M	-78.77M	-20.45M	-23.08M	-44.35M	-18.48M	-26.61M	-34M	-28.78M	-41.64M
EBITDA Margin %	-255.28%	-120.63%	-69.34%	-	-	-	-	-	-	-
EBITDA Growth %	-0.49%	-0.11%	0.74%	-0.13%	-0.92%	0.58%	-0.44%	-0.28%	0.15%	-0.45%
D&A (Non-Cash Add-back)	1.29M	2.24M	28K	32K	1.05M	815K	374K	638K	381K	389K
EBIT	-73.14M	-82.06M	-84.3M	-27.04M	-44.57M	-19.21M	-27.02M	-34.09M	-28.04M	-40.53M
Net Interest Income+	0	0	0	0	264K	90K	-1.28M	-1.07M	-334K	183K
Interest Income	0	0	0	0	264K	90K	1.28K	549K	1.11M	1.5M
Interest Expense	436K	659K	0	134K	0	0	1.28M	1.62M	1.45M	1.32M
Other Income/Expense	-1.15M	-6.45M	-64.1M	-4.06M	831K	90K	-1.32M	-1.07M	-334K	183K
Pretax Income+	-73.14M	-82.06M	-84.59M	-27.18M	-44.57M	-19.21M	-28.3M	-35.71M	-29.49M	-41.84M
Pretax Margin %	-264.06%	-125.66%	-286.73%	-	-	-	-	-	-	-
Income Tax+	75K	201K	67K	-169K	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-73.22M	-82.26M	-84.58M	-27.19M	-44.57M	-19.12M	-28.3M	-35.71M	-29.49M	-41.84M
Net Margin %	-264.33%	-125.97%	-286.71%	-	-	-	-	-	-	-
Net Income Growth %	-0.48%	-0.12%	-0.03%	0.68%	-0.64%	0.57%	-0.48%	-0.26%	0.17%	-0.42%
Net Income (Continuing)	-73.22M	-82.26M	-84.59M	-27.18M	-44.57M	-19.21M	-28.3M	-35.71M	-29.49M	-41.84M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	12.76M	2.17M	1.32M	0	0	0	0	0
EPS (Diluted)+	-608.25	-575.73	-72406.33	-263.65	-48.77	-612.56	-7.80	-3.18	-1.91	-1.50
EPS Growth %	-0.24%	0.05%	-124.76%	1%	0.82%	-11.56%	0.99%	0.59%	0.4%	0.21%
EPS (Basic)	-608.25	-575.73	-72406.33	-263.65	-48.77	-612.56	-7.80	-3.18	-1.91	-1.50
Diluted Shares Outstanding	120.38K	142.88K	1.17K	103.14K	913.78K	31.21K	291.56K	888.38K	15.42M	27.9M
Basic Shares Outstanding	120.38K	142.88K	1.17K	103.14K	913.78K	31.21K	291K	888K	15.42M	27.9M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	129.86M	116.44M	19.74M	83.42M	71.13M	19.82M	68.96M	32.95M	40.36M	31.47M
Cash & Short-Term Investments	126.86M	114.39M	67.2M	77.72M	63.51M	18.82M	51.83M	31.23M	39.23M	30.27M
Cash Only	43.42M	43.93M	15.7M	73.33M	63.51M	18.82M	51.83M	31.23M	39.23M	30.27M
Short-Term Investments	83.44M	70.46M	51.5M	4.38M	0	0	0	0	0	0
Accounts Receivable	0	0	1.03M	2.33M	1.28M	260K	15M	450K	0	0
Days Sales Outstanding	-	-	1.28K	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	3M	2.06M	1.58M	3.37M	6.34M	59K	553K	263K	96K	535K
Total Non-Current Assets+	8.75M	6.1M	74K	652K	3.84M	3.04M	4.28M	13.14M	11.24M	10.01M
Property, Plant & Equipment	8.31M	5.57M	3.11M	0	3.33M	2.99M	4.16M	12.71M	10.79M	9.53M
Fixed Asset Turnover	0.03x	0.12x	0.09x	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	439K	504K	146K	439K	0	0	0	0	0	388K
Other Non-Current Assets	0	23K	-3.19M	213K	507K	51K	111K	429K	448K	97K
Total Assets+	138.61M	122.54M	19.81M	84.07M	74.97M	22.86M	73.24M	46.09M	51.6M	41.49M
Asset Turnover	0.00x	0.01x	0.01x	-	-	-	-	-	-	-
Asset Growth %	1.11%	-0.12%	-0.84%	3.24%	-0.11%	-0.7%	2.2%	-0.37%	0.12%	-0.2%
Total Current Liabilities+	11.24M	13.21M	4.09M	9.82M	12.52M	3.22M	20.03M	7.28M	9.41M	14.22M
Accounts Payable	3.35M	2.18M	2.24M	2M	1.5M	1.07M	991K	1.11M	845K	2.45M
Days Payables Outstanding	544.01	147.53	29.23K	22.79K	-	479.65	-	-	-	2.3K
Short-Term Debt	0	0	174K	189K	1.96M	0	0	0	4.29M	6.35M
Deferred Revenue (Current)	0	0	334K	0	0	0	0	0	0	0
Other Current Liabilities	7.89M	11.03M	2.29M	7.63M	7.02M	774K	912K	1.25M	1.79M	0
Current Ratio	11.55x	8.82x	4.82x	8.50x	5.68x	6.15x	3.44x	4.53x	4.29x	2.21x
Quick Ratio	11.55x	8.82x	4.82x	8.50x	5.68x	6.15x	3.44x	4.53x	4.29x	2.21x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	520K	1.12M	738K	1.14M	2.58M	88.43M	17.09M	20.7M	15.42M	8.14M
Long-Term Debt	0	0	599K	383K	168K	0	15.07M	10.37M	6.26M	0
Capital Lease Obligations	0	0	0	0	2.4M	1.73M	2.03M	10.33M	9.16M	8.14M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	520K	1.12M	139K	752K	16K	86.71M	0	0	0	0
Total Liabilities	11.76M	14.32M	4.83M	10.95M	15.1M	91.66M	37.12M	27.98M	24.84M	22.36M
Total Debt+	0	0	773K	572K	4.52M	2.44M	18.54M	22.11M	20.66M	15.37M
Net Debt	-43.42M	-43.93M	-16.85M	-72.76M	-58.99M	-16.38M	-33.29M	-9.12M	-18.57M	-14.9M
Debt / Equity	-	-	0.05x	0.01x	0.08x	-	0.51x	1.22x	0.77x	0.80x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-165.14x	-122.93x	-	-172.51x	-	-	-21.05x	-21.41x	-20.12x	-31.93x
Total Equity+	126.85M	108.22M	14.98M	73.12M	59.87M	-68.79M	36.12M	18.11M	26.77M	19.13M
Equity Growth %	1.29%	-0.15%	-0.86%	3.88%	-0.18%	-2.15%	1.53%	-0.5%	0.48%	-0.29%
Book Value per Share	1053.77	757.41	12827.91	708.99	65.52	-2204.20	123.87	20.39	1.74	0.69
Total Shareholders' Equity	126.85M	108.22M	2.23M	70.95M	58.55M	-68.79M	36.12M	18.11M	26.77M	19.13M
Common Stock	27K	36K	36K	13K	18K	1K	7K	11K	22K	44K
Retained Earnings	-167.92M	-250.18M	-136.89M	-164.09M	-208.65M	-71.76M	-100.06M	-135.77M	-165.26M	-207.11M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-170K	-60K	-19K	148K	165K	0	0	0	0	0
Minority Interest	0	0	12.76M	2.17M	1.32M	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-50.29M	-61.73M	-20.34M	-23.65M	-41.22M	-19.02M	-25.96M	-31.07M	-27.36M	-33.03M
Operating CF Margin %	-181.54%	-94.54%	-68.95%	-	-	-	-	-	-	-
Operating CF Growth %	-0.64%	-0.23%	0.67%	-0.16%	-0.74%	0.54%	-0.36%	-0.2%	0.12%	-0.21%
Net Income	-73.22M	-82.26M	-84.58M	-27.19M	-44.57M	-19.21M	-28.3M	-35.71M	-29.49M	-41.84M
Depreciation & Amortization	1.29M	2.24M	1.65M	32K	1.05M	339K	374K	638K	381K	389K
Stock-Based Compensation	19.34M	9.21M	6.89M	1.43M	0	453K	1.1M	1.56M	2.55M	5.3M
Deferred Taxes	0	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	0	0	66.05M	0	4.35M	470K	1.48M	1.57M	1.88M	1.51M
Working Capital Changes	-532K	4.58M	-1.84M	1.04M	-2.05M	-1.07M	-613K	868K	-2.68M	1.61M
Change in Receivables	0	0	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	-171K	-1.18M	-1.45M	320K	-469K	-574K	-209K	1K	-263K	1.6M
Cash from Investing+	-38.29M	8.29M	458K	1.12M	3.99M	-6K	-97K	-562K	-170K	-435K
Capital Expenditures	-5.23M	-2.59M	-158K	-36K	-397K	-50K	-135K	-562K	-170K	-435K
CapEx % of Revenue	18.88%	3.96%	0.54%	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-681K	0	-1.45M	0	0	44K	38K	0	0	0
Cash from Financing+	125.39M	54.15M	-4.46M	78.55M	26.94M	34.6M	59.06M	11.4M	35.6M	24.5M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	0	0	33.32M	0	-401K	10.64M	0	0	307K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-55.52M	-64.32M	-20.34M	-23.68M	-41.62M	-19.07M	-26.09M	-31.63M	-27.53M	-33.46M
FCF Margin %	-200.42%	-98.5%	-68.96%	-	-	-	-	-	-	-
FCF Growth %	-0.66%	-0.16%	0.68%	-0.16%	-0.76%	0.54%	-0.37%	-0.21%	0.13%	-0.22%
FCF per Share	-461.18	-450.17	-17417.81	-229.63	-45.55	-610.93	-89.49	-35.61	-1.79	-1.20
FCF Conversion (FCF/Net Income)	0.69x	0.75x	0.24x	0.87x	0.92x	0.99x	0.92x	0.87x	0.93x	0.79x
Interest Paid	0	0	0	0	0	0	0	1.54M	1.25M	1.18M
Taxes Paid	0	0	0	0	0	0	0	18K	191K	54K

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-80.38%	-69.99%	-137.3%	-61.73%	-67.02%	-	-78.36%	-131.7%	-131.42%	-182.35%
Return on Invested Capital (ROIC)	-81.61%	-82.26%	-47.75%	-8335.1%	-5474.16%	-	-	-439.59%	-254.36%	-507.48%
Gross Margin	-711.91%	-727.11%	90.51%	-	-	-	-	-	-	-
Net Margin	-26432.85%	-12597.24%	-28670.51%	-	-	-	-	-	-	-
Debt / Equity	-	-	0.05x	0.01x	0.08x	-	0.51x	1.22x	0.77x	0.80x
Interest Coverage	-165.14x	-122.93x	-	-172.51x	-	-	-21.05x	-21.41x	-20.12x	-31.93x
FCF Conversion	0.69x	0.75x	0.24x	0.87x	0.92x	0.99x	0.92x	0.87x	0.93x	0.79x
Revenue Growth	-97.15%	135.74%	-54.82%	-100%	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Tempest Therapeutics, Inc. (TPST) grew revenue by 0.0% over the past year. Growth has been modest.

Tempest Therapeutics, Inc. (TPST) reported a net loss of $36.1M for fiscal year 2024.

Dividend & Returns

Tempest Therapeutics, Inc. (TPST) has a return on equity (ROE) of -182.3%. Negative ROE indicates the company is unprofitable.

Tempest Therapeutics, Inc. (TPST) had negative free cash flow of $33.4M in fiscal year 2024, likely due to heavy capital investments.